At the Retina World Congress in Fort Lauderdale, Florida, on May 5, 2025, at 5:32 PM, Dr. Rishi P. Singh will share findings from the Phase 2a SIGLEC study, which assessed the safety and efficacy of a single dose of AVD-104 for the treatment of geographic atrophy. #glycoimmunology #biotech #innovation #ophthalmology #retina #GA #AMD #macula
Aviceda Therapeutics’ Post
Explore content categories
- Career
- Productivity
- Finance
- Soft Skills & Emotional Intelligence
- Project Management
- Education
- Technology
- Leadership
- Ecommerce
- User Experience
- Recruitment & HR
- Customer Experience
- Real Estate
- Marketing
- Sales
- Retail & Merchandising
- Science
- Supply Chain Management
- Future Of Work
- Consulting
- Writing
- Economics
- Artificial Intelligence
- Employee Experience
- Workplace Trends
- Fundraising
- Networking
- Corporate Social Responsibility
- Negotiation
- Communication
- Engineering
- Hospitality & Tourism
- Business Strategy
- Change Management
- Organizational Culture
- Design
- Innovation
- Event Planning
- Training & Development
Looking forward to it!